Management of rising prostate-specific antigen following a negative biopsy

Review

J Stephen Jones. Curr Opin Urol. 2010 May.

. 2010 May;20(3):198-203.

doi: 10.1097/mou.0b013e3283385fbd.

No abstract available

Similar articles

PSA: the plot thickens.
[No authors listed] [No authors listed] Health News. 2003 Oct;9(10):15. Health News. 2003. PMID: 14619777 No abstract available.
Development and validation of a nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session in the era of extended prostate sampling.
Moussa AS, Jones JS, Yu C, Fareed K, Kattan MW. Moussa AS, et al. BJU Int. 2010 Nov;106(9):1309-14. doi: 10.1111/j.1464-410X.2010.09362.x. BJU Int. 2010. PMID: 20438566
Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.
Narayan P, Fournier G, Gajendran V, Leidich R, Lo R, Wolf JS Jr, Jacob G, Nicolaisen G, Palmer K, Freiha F. Narayan P, et al. Urology. 1994 Oct;44(4):519-24. doi: 10.1016/s0090-4295(94)80050-2. Urology. 1994. PMID: 7524237 Clinical Trial.
Optimizing prostate biopsy.
Bostanci Y, Kazzazi A, Djavan B. Bostanci Y, et al. Minerva Urol Nefrol. 2012 Dec;64(4):233-43. Minerva Urol Nefrol. 2012. PMID: 23288210 Review.
Defining prostate cancer risk before prostate biopsy.
Pal RP, Maitra NU, Mellon JK, Khan MA. Pal RP, et al. Urol Oncol. 2013 Nov;31(8):1408-18. doi: 10.1016/j.urolonc.2012.05.012. Epub 2012 Jul 12. Urol Oncol. 2013. PMID: 22795499 Review.

Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens.
Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Crawford ED, et al. Prostate. 2013 May;73(7):778-87. doi: 10.1002/pros.22622. Epub 2012 Nov 20. Prostate. 2013. PMID: 23169245 Free PMC article.